Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yino Pharma is a China-based pharmaceutical ingredients manufacturer focused on heparin-derived anticoagulant active pharmaceutical ingredients. The company operates a vertically integrated, closed-loop production model from animal-sourced raw material collection through API manufacturing, with EU-GMP-certified operations highlighted for multiple heparin products. Its marketed portfolio includes heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, and nadroparin calcium, with additional heparin derivatives and other biologically active substances referenced in company materials. Yino Pharma appears to serve pharma manufacturers and international customers as a supplier of anticoagulant APIs rather than as a developer of novel therapeutic drugs. The company also maintains a European entity, Yino Pharma Europe GmbH, in Hamburg to support regulatory and commercial activities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on YinoPharma.